APOE3
Revvity Gets CE Mark for PCR Test Used to Guide Alzheimer's Therapy
Revvity's Euroimmun subsidiary has launched the EuroRealTime APOE assay in Europe for the detection and differentiation of common forms of the APOE gene.
Qiagen, Eli Lilly Collaborate on Alzheimer's Risk Dx Panel
The firms will develop a multiplex PCR panel for the QiaStat-Dx system that detects APOE genotypes.
Dominant Alzheimer's Disease Delayed in Individuals Heterozygous for Protective APOE3 Variant
Researchers saw a protective effect in a Colombian cohort with autosomal dominant Alzheimer's disease for those who were heterozygous for the APOE3 Christchurch variant.
Late-Onset Alzheimer's Disease Features Thwarted by Protective Variant
A homozygous version of the Christchurch variant appeared to reduce disease-related features in mouse models and cells containing a late-onset Alzheimer's-linked APOE4 mutation.
Alzheimer's Disease Study Traces Factors Affecting APOE Variant Risk, Protective Effects
Researchers analyzed genetic and other data for almost 68,800 individuals to better understand ancestry, sex, and age interactions with risky and protective APOE genotypes.